Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study.
Saved in:
| Title: | Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study. |
|---|---|
| Authors: | Cousin S; Medical Oncology Department, Institut Bergonié, Bordeaux, France., Blay JY; Medical Oncology Department, Centre Léon Bérard, Lyon, France., Garcia IB; Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institut of Oncology (VHIO), Barcelona, Spain., de Bono JS; The Institute of Cancer Research and Royal Marsden Hospital, London, UK., Le Tourneau C; Department of Drug Development and Innovation (D3i), INSERM U900 Research Unit, Institut Curie, Paris-Saclay University, Paris and Saint-Cloud, France., Moreno V; Medical Oncology, START Madrid-FJD, Fundación Jiménez Díaz Hospital, Madrid, Spain., Trigo J; Medical Oncology Department, Hospital Universitario Virgen de la Victoria y Regional, IBIMA, Málaga, Spain., Hann CL; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Azad AA; Peter MacCallum Cancer Centre, Victoria, Australia., Im SA; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea., Cassier PA; Medical Oncology Department, Centre Léon Bérard, Lyon, France., French CA; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA., Italiano A; Early Phase Trials and Sarcoma Units, Institut Bergonié, Bordeaux, France., Keedy VL; Department of Medicine, Hematology and Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA., Plummer R; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK., Sablin MP; Department of Drug Development and Innovation (D3i), INSERM U900 Research Unit, Institut Curie, Paris-Saclay University, Paris and Saint-Cloud, France., Hemming ML; Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA., Ferron-Brady G; GSK, Collegeville, Pennsylvania, USA., Wyce A; GSK, Collegeville, Pennsylvania, USA., Khaled A; GSK, Collegeville, Pennsylvania, USA., Datta A; GSK, Collegeville, Pennsylvania, USA., Foley SW; GSK, Collegeville, Pennsylvania, USA., McCabe MT; GSK, Collegeville, Pennsylvania, USA., Wu Y; GSK, Collegeville, Pennsylvania, USA., Horner T; GSK, Collegeville, Pennsylvania, USA., Kremer BE; GSK, Collegeville, Pennsylvania, USA., Dhar A; GSK, Collegeville, Pennsylvania, USA., O'Dwyer PJ; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Shapiro GI; Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA., Piha-Paul SA; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. |
| Source: | International journal of cancer [Int J Cancer] 2022 Mar 15; Vol. 150 (6), pp. 993-1006. Date of Electronic Publication: 2021 Nov 26. |
| Publication Type: | Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0042124 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0215 (Electronic) Linking ISSN: 00207136 NLM ISO Abbreviation: Int J Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1097-0215 |
|---|---|
| DOI: | 10.1002/ijc.33861 |
